Fig. 2

The predict efficiencies of eIF3i and eIF3k in gliomas. ROC curves showed the predictive efficiencies of eIF3i, eIF3k, combination of eIF3i and eIF3k, WHO grade and subgroups of WHO 2016 integrated diagnosis (Oligodendroglioma, IDH-mutant, 1p/19q codeletion; Astrocytoma, IDH-mutant; Astrocytoma, IDH-wildtype) on 3-year (a) and 5-year survival (b) in LGG of CGGA dataset. ROC curves showed the predictive efficiencies of eIF3i, eIF3k and combination of eIF3i and eIF3k on 14.4-month (c) and 24-month survival (d) in GBM of CGGA dataset